People with chronic thromboembolic pulmonary hypertension (CTEPH) continue to experience significant symptoms that interfere with daily life, even when receiving treatment, according to a real-world U.S. study. The study also found that people treated at Pulmonary Hypertension Association (PHA)-accredited centers tended to have more severe…
Having more severe bronchopulmonary dysplasia (BPD) — a chronic lung disease that occurs when a baby’s lungs aren’t fully developed — does not predict worse pulmonary hypertension (PH) in infants born preterm, according to a new study that used data from a patient registry. The researchers found that BPD is…
A 68-year-old man with severe pulmonary arterial hypertension, or PAH — high blood pressure in the lungs — and multiple coexisting conditions saw considerable improvements after being given combination therapy with four different medications, a case study from the U.S. reports. Gains were seen in blood flow measures, the…
Treatment with inhaled nitric oxide (iNO) and pulmonary surfactant within the first three days of life significantly reduces the risk of developing bronchopulmonary dysplasia (BPD) associated with pulmonary hypertension (PH) in preterm infants, according to a recent study in China. “Early intervention using iNO and PS appears to be…
Ten members of the pulmonary hypertension (PH) community were honored by the Pulmonary Hypertension Association (PHA) for their dedication and service. The Outstanding Member Awards ceremony took place Aug. 17 at the PHA 2024 International PH Conference and Scientific Sessions in Indianapolis. The awards honor people who’ve shown exceptional dedication…
Health Canada has approved Merck’s Winrevair (sotatercept-csrk) for adults with pulmonary arterial hypertension (PAH). The approval specifically covers the use of Winrevair in combination with standard therapies to treat patients with World Health Organization (WHO) functional classification 2 or 3. The decision follows approvals in the U.S., as…
Tenax Therapeutics has raised about $100 million in private funding to help accelerate the clinical development of oral levosimendan (TNX-103), a potential therapy for pulmonary hypertension(PH) due to heart failure with preserved ejection fraction (PH-HFpEF). The funding will help complete the ongoing placebo-controlled Phase 3 LEVEL…
The U.S. Food and Drug Administration (FDA) has given orphan drug designation to ZM001, a first-in-class investigational antibody from Zymedi for pulmonary arterial hypertension (PAH). ZM001 is intended to reduce inflammation and tissue fibrosis (or scarring) in people with PAH. A Phase 1 clinical trial (NCT05967299) began dosing…
Patients with an intermediate to high risk of mortality in the first year following a pulmonary arterial hypertension (PAH) diagnosis have poorer health-related quality of life than those at lower risk, according to a study in England. Those costs were reduced following diagnosis, mainly due to less spending…
High blood levels of resistin, a hormone produced by fat cells, may help identify pulmonary arterial hypertension (PAH) patients at higher risk of clinical worsening, a large U.S. study suggests. Resistin levels also could separate people with idiopathic, or unknown cause, PAH (iPAH) or…
A natural substance isolated from a houseplant shows promise as a potential treatment to prevent and reverse pulmonary hypertension (PH), a study found. Treatment with FR900359 (FR) reversed the disease in a mouse model of PH, and relaxed pulmonary arteries of mice, pigs, and humans. FR activity was equivalent…
Reviva Pharmaceuticals has been granted a patent in Europe that covers using brilaroxazine, formerly RP5063, for pulmonary hypertension (PH). The patent covers patients with pulmonary arterial hypertension (PAH) and those who develop PH associated with chronic obstructive pulmonary disease (COPD), an inflammatory lung disorder, or sickle…
Get regular updates to your inbox.
